Teimouri Fatemeh, Kebriaeezadeh Abbas, Zahraei Seyed Mohsen, Gheiratian MohammadMahdi, Nikfar Shekoufeh
Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Daru. 2017 Jan 14;25(1):1. doi: 10.1186/s40199-017-0166-0.
Health decision makers need to know the impact of the development of a new intervention on the public health and health care costs so that they can plan for economic and financial objectives. The aim of this study was to determine the budget impact of adding Haemophilus influenzae type b (Hib) as a part of a Pentavalent vaccine (Hib-HBV-DTP) to the national childhood immunization schedule of Iran.
An excel-based model was developed to determine the costs of including the Pentavalent vaccine in the national immunization program (NIP), comparing the present schedule with the previous one (including separate DTP and hepatitis B vaccines). The total annual costs included the cost of vaccination (the vaccine and syringe) and the cost of Hib treatment. The health outcome was the estimated annual cases of the diseases. The net budget impact was the difference in the total annual cost between the two schedules. Uncertainty about the vaccine effectiveness, vaccination coverage, cost of the vaccine, and cost of the diseases were handled through scenario analysis.
The total cost of vaccination during 5 years was $18,060,463 in the previous program and $67,774,786 in the present program. Inclusion of the Pentavalent vaccine would increase the vaccination cost about $49 million, but would save approximately $6 million in the healthcare costs due to reduction of disease cases and treatment costs. The introduction of the Pentavalent vaccine resulted in a net increase in the healthcare budget expenditure across all scenarios from $43.4 million to $50.7 million.
The results of this study showed that the inclusion of the Pentavalent vaccine in the NIP of Iran had a significant impact on the health care budget and increased the financial burden on the government. Budget impact of including Pentavalent vaccine in the national immunization schedule of Iranᅟ.
卫生决策者需要了解新干预措施的发展对公共卫生和医疗保健成本的影响，以便他们能够规划经济和财务目标。本研究的目的是确定将b型流感嗜血杆菌（Hib）作为五价疫苗（Hib-HBV-DTP）的一部分纳入伊朗国家儿童免疫规划的预算影响。
开发了一个基于Excel的模型，以确定将五价疫苗纳入国家免疫规划（NIP）的成本，将当前规划与之前的规划（包括单独的百白破疫苗和乙肝疫苗）进行比较。年度总成本包括疫苗接种成本（疫苗和注射器）以及Hib治疗成本。健康结果是疾病的估计年度病例数。净预算影响是两个规划之间年度总成本的差异。通过情景分析处理疫苗效力、疫苗接种覆盖率、疫苗成本和疾病成本的不确定性。
在前一个规划中，5年期间的疫苗接种总成本为18,060,463美元，在当前规划中为67,774,786美元。纳入五价疫苗将使疫苗接种成本增加约4900万美元，但由于疾病病例和治疗成本的减少，将节省约600万美元的医疗保健成本。引入五价疫苗导致所有情景下医疗保健预算支出净增加，从4340万美元到5070万美元不等。
本研究结果表明，将五价疫苗纳入伊朗的国家免疫规划对医疗保健预算有重大影响，并增加了政府的财政负担。将五价疫苗纳入伊朗国家免疫规划的预算影响。
